Opiant Pharmaceuticals, Inc. (OPNT): Price and Financial Metrics

Opiant Pharmaceuticals, Inc. (OPNT): $20.65

0.12 (-0.58%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

OPNT Price/Volume Stats

Current price $20.65 52-week high $29.25
Prev. close $20.77 52-week low $7.34
Day low $20.50 Volume 562,700
Day high $21.00 Avg. volume 77,920
50-day MA $20.48 Dividend yield N/A
200-day MA $14.66 Market Cap 106.64M

OPNT Stock Price Chart Interactive Chart >


Opiant Pharmaceuticals, Inc. (OPNT) Company Bio


Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is based in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.


OPNT Latest News Stream


Event/Time News Detail
Loading, please wait...

OPNT Latest Social Stream


Loading social stream, please wait...

View Full OPNT Social Stream

Latest OPNT News From Around the Web

Below are the latest news stories about OPIANT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate OPNT as an investment opportunity.

Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%

Key Insights The considerable ownership by individual investors in Opiant Pharmaceuticals indicates that they...

Yahoo | February 22, 2023

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign In

Yahoo | February 7, 2023

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute th

Yahoo | February 6, 2023

UPDATE 2-U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals

Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics , and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November. "Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market," she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats.

Yahoo | January 26, 2023

U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals

WASHINGTON (Reuters) -Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics, and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.

Yahoo | January 26, 2023

Read More 'OPNT' Stories Here

OPNT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 91.91%
5-year 67.89%
YTD N/A
2023 0.00%
2022 -39.70%
2021 318.80%
2020 -44.24%
2019 -0.35%

Continue Researching OPNT

Here are a few links from around the web to help you further your research on Opiant Pharmaceuticals Inc's stock as an investment opportunity:

Opiant Pharmaceuticals Inc (OPNT) Stock Price | Nasdaq
Opiant Pharmaceuticals Inc (OPNT) Stock Quote, History and News - Yahoo Finance
Opiant Pharmaceuticals Inc (OPNT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!